Prevalence, characteristics, and treatment outcome of congenital malaria in Nigeria: a systematic review by Emmanuel Kokori, Gbolahan Olatunji, Bonaventure Michael Ukoaka, Israel Charles Abraham, Rosemary Komolafe, Victor Oluwatomiwa Ajekiigbe, Ntishor Gabriel Udam, Stanley Eneh, Chidiogo Ezenwoba, Adetola Emmanuel Babalola, Oluwatobi Omoworare, Nicholas Aderinto

“…Treatment regimens included a variety of antimalarial drugs, such as chloroquine, sulfadoxine-pyrimethamine, amodiaquine, quinine, and artemisinin-based combination therapy. While treatment outcomes were generally positive, some studies reported complications and deaths. …”
Get full text

Novel Antibiotic Combinations of Diverse Subclasses for Effective Suppression of Extensively Drug-Resistant Methicillin-Resistant Staphylococcus aureus (MRSA) by Shumyila Nasir, Muhammad Sufyan Vohra, Danish Gul, Umm E Swaiba, Maira Aleem, Khalid Mehmood, Saadia Andleeb

“…The treatment process is further complicated with the development of resistance to glycopeptides, primary antibiotics for treatment of MRSA. Antibiotic combination therapy with existing antimicrobial agents may provide an immediate treatment option. …”
Get full text

Curative Effect of AD-MSCs against Cisplatin-Induced Hepatotoxicity in Rats is Potentiated by Azilsartan: Targeting Oxidative Stress, MAPK, and Apoptosis Signaling Pathways by Amany Abdlrehim Bekhit, Olivia N. Beshay, Michael A. Fawzy, Sara Mohamed Naguib Abdel-Hafez, Gaber El-Saber Batiha, Farid S. Ataya, Moustafa Fathy

“…Moreover, treatment with combination therapy (AZIL.L or H + AD-MSCs) considerably mitigated all previously mentioned alterations superior to AZIL or AD-MSCs alone, which might be attributed to the AZIL-enhanced homing ability of AD-MSCs into the injured liver tissue. …”
Get full text

Real-World Evidence Evaluation on the Lipid Profile, Therapeutic Goals, and Safety of the Fixed-Dose Combination of Rosuvastatin/Ezetimibe (Trezete®) in Dyslipidemia Patients by Joel Rodríguez-Saldaña, Francisco Padilla-Padilla, Ernesto G. Cardona-Muñoz, Yulia Romero-Antonio, María Marcela Arguedas-Núñez, José G. Sander-Padilla, Alberto Martínez-Muñoz, Laura A. Lugo-Sánchez, Ileana C. Rodríguez-Vazquez, Jorge González-Canudas

“…It is relevant to mention that a significant percentage of patients achieved therapeutic goals during the first months of treatment. Fixed-dose combination therapy has shown to be as safe as monotherapy treatment. …”
Get full text

Metformin and Probiotics Interplay in Amelioration of Ethanol-Induced Oxidative Stress and Inflammatory Response in an In Vitro and In Vivo Model of Hepatic Injury by Farhin Patel, Kirti Parwani, Dhara Patel, Palash Mandal

“…Therefore, we investigated the effectiveness of combination therapy using a mixture of eight strains of lactic acid-producing bacteria, commercialized as Visbiome® (V) and Met in preventing the ethanol-induced hepatic injury using in vitro and in vivo models. …”
Get full text

The antihypertensive efficacy of a quadruple single-pill combination in patients with resistant hypertension: study protocol for a randomized, open-label, crossover trial by Yuanyuan Yao, Xin Zhang, Runyu Ye, Shanshan Jia, Xiangyu Yang, Xiaoping Chen

“…The two groups will receive different combination therapies for 6 weeks and will then switch to the other combination therapy for 6 weeks, with a 4-week wash-out. …”
Get full text

One Earth-One Health (OE-OH): Antibacterial Effects of Plant Flavonoids in Combination with Clinical Antibiotics with Various Mechanisms by Ganjun Yuan, Fengxian Lian, Yu Yan, Yu Wang, Li Zhang, Jianping Zhu, Aiman Fatima, Yuxing Qian

“…<b>Background/Objectives:</b> Antimicrobial resistance (AMR) poses a significant threat to human health, and combination therapy has proven effective in combating it. …”
Get full text

Platelet-rich fibrin and silver nano-particles loaded chitosan treatment for post- laminectomy epidural scar adhesions: in vivo rats study model by Samah Fouad, Awad Rizk, Esam Mosbah, Mostafa M. Nabeeh, Walaa Awadin, Ayman S. Elmezayyen, Ekramy Elmorsy, Adel Zaghloul

“…Conclusion The use of PRF with Chi/Ag-NPs as nano biomaterials could be considered a combination therapy for the reduction of EF post-laminectomy in a rat model.…”
Get full text

Identification of CβS and ODC antimony resistance markers in anthroponotic cutaneous leishmaniasis field isolates by gene expression profiling by Farzaneh Zarrinkar, Iraj Sharifi, Razieh Tavakoli Oliaee, Ali Afgar, Elaheh Molaakbari, Mehdi Bamorovat, Zahra Babaei, Ebrahim Eskandari, Ehsan Salarkia, Marzieh Asadi

“…Alternative drugs or combination therapy and monitoring drug resistance to prevent the spread of resistant isolates are proper strategies to control the disease.…”
Get full text

Artificial intelligence-derived gut microbiome as a predictive biomarker for therapeutic response to immunotherapy in lung cancer: protocol for a multicentre, prospective, observat... by Ryo Toyozawa, Fumihiro Shoji, Takanori Yamashita, Fumihiko Kinoshita, Shinkichi Takamori, Takatoshi Fujishita, Kensaku Ito, Koji Yamazaki, Naoki Nakashima, Tatsuro Okamoto

“…The main inclusion criteria are as follows: (1) pathologically or cytologically confirmed metastatic or postoperative recurrent lung cancer including non-small cell lung cancer and small cell lung cancer; (2) age≥20 years at the time of informed consent; (3) planned treatment with immunotherapy including combination therapy and monotherapy, as the first-line immunotherapy; and (4) ability to provide faecal samples. …”
Get full text

The Effectiveness of Varying Combination Ratios of A. cordifolia and M. indica against Field and Laboratory Strains of P. falciparum In Vitro by Yakubu Jibira, Elizabeth Cudjoe, Frederick M. Tei-Maya, Benjamin Ayensu, Linda E. Amoah

“…There is therefore an urgent need to identify new drug candidates that will be effective against the existing malaria parasites. Drug combination therapy presents a myriad of advantages over monotherapy including delayed onset of resistance, potentiation, and synergism. …”
Get full text

Comparative analysis of combined methylene blue photodynamic therapy and doxorubicin treatment of oral squamous cell carcinoma cell line: In vitro study on apoptosis by Shayan Momeni Goujani, Maryam Koopaie, Fateme Hamta Safarian, Neda Hakimiha, Shima Younespour

“…Introduction: Squamous cell carcinoma (SCC) is the most common malignancy of the head and neck region. Combination therapy potentially enhances the effectiveness beyond that of each treatment alone. …”
Get full text

Effect of Hydroxychloroquine and Azithromycin on QT Interval Prolongation and Other Cardiac Arrhythmias in COVID-19 Confirmed Patients by Seyed Parsa Eftekhar, Sohrab Kazemi, Mohammad Barary, Mostafa Javanian, Soheil Ebrahimpour, Naghmeh Ziaei

“…The mean age of patients was 59.2±15.4.The mean of posttreatment QTc interval in the monotherapy group was shorter than the mean of posttreatment QTc interval in the combination therapy group, but it had no significant statistical difference (462.5±43.1 milliseconds vs. 464.3±59.1 milliseconds; p=0.488). …”
Get full text

The prognosis and metabolite changes of NSCLC patients receiving first‐line immunotherapy combined chemotherapy in different M1c categories according to 9th edition of TNM classifi... by Liang Zheng, Fang Hu, Wei Nie, Jun Lu, Bo Zhang, Jianlin Xu, Shuyuan Wang, Ying Li, Xiaoxuan Zheng, Wei Zhang, Yinchen Shen, Runbo Zhong, Tianqing Chu, Baohui Han, Hua Zhong, Xueyan Zhang

“…The relationship between metastatic patterns and progression‐free survival (PFS) in patients undergoing combination therapy was analyzed using univariate and multivariate Cox regression models. …”
Get full text

Temporary spinal cord stimulation combined with lidocaine patch for postherpetic neuralgia in the elderly: a controlled study by Yun Li, Chunhui Hao, Shengtao Wang, Feng Qiu, Xuli Zhao, Tao Sun

“…Patients with PHN duration &lt;60 days benefited more from combination therapy. Adverse events were minimal and similar between groups.ConclusionCombining SCS with lidocaine patches significantly enhances pain relief and sleep quality in elderly PHN patients compared to SCS alone. …”
Get full text

A Smart Nanomedicine Unleashes a Dual Assault of Glucose Starvation and Cuproptosis to Supercharge αPD‐L1 Therapy by Yiming Xu, Yuan Wu, Xinjie Zheng, Dongxue Wang, Hangqi Ni, Weiyu Chen, Kai Wang

“…Abstract Combination therapy has become a promising strategy for promoting the outcomes of anti‐programmed death ligand‐1 (αPD‐L1) therapy in lung cancer. …”
Get full text

Natural products targeting RAS by multiple mechanisms and its therapeutic potential in cancer: An update since 2020 by Yanqing Liu, Jie Chen, Xiang Li, Yu Fan, Cheng Peng, Xiaochun Ye, Yingshuang Wang, Xin Xie

“…Strategies such as combination therapy, structural optimization, and drug delivery systems are anticipated to enhance efficacy and overcome these challenges.…”
Get full text

Repression of PFKFB3 sensitizes ovarian cancer to PARP inhibitors by impairing homologous recombination repair by Yinan Xiao, Yu Wu, Qilong Wang, Mo Li, Chaolin Deng, Xiaoyang Gu

“…The in vivo efficacy of PARPi and PFK158 combination therapy was evaluated in OC xenograft models. …”
Get full text

TLR7/8/9 agonists and low-dose cisplatin synergistically promotes tertiary lymphatic structure formation and antitumor immunity by Shuting Wu, Rong Xiang, Yiwei Zhong, Shushu Zhao, Zhiyu Zhang, Zhihua Kou, Shijie Zhang, Yi Zhao, Cheng Zu, Gan Zhao, Yanling Xiao, Sulin Ren, Xiaoming Gao, Bin Wang

“…Abstract In situ vaccination (ISV) triggers antitumor immune responses using the patient’s own cancer antigens, yet limited neoantigen release hampers its efficacy. Our novel combination therapy involves low-dose local cisplatin followed by ISV with a TLR7/8/9 agonist formulation (CR108), in which CR108 boosts and sustains the antitumor responses induced by the cisplatin-released neoantigens. …”
Get full text

A Systematic Review of the Prevalence and Diagnostic Workup of PIK3CA Mutations in HR+/HER2– Metastatic Breast Cancer by Elizabeth J. Anderson, Lea E. Mollon, Joni L. Dean, Terri L. Warholak, Ayal Aizer, Emma A. Platt, Derek H. Tang, Lisa E. Davis

“…Recent evidence suggests combination therapy with the PI3K inhibitor (PI3Ki) alpelisib and endocrine therapy (ET) improves response rates and progression-free survival (PFS) in PIK3CA-mutant, hormone receptor positive (HR+) BC versus ET alone; thus, better understanding the clinical and epidemiologic elements of these mutations is warranted. …”
Get full text